Evidence map›Paper›PMID 28799406›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2017

A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma.

Alessandra Franzoni, Elitza Markova-Car, Sanja Dević-Pavlić, Davor Jurišić, Cinzia Puppin, Catia Mio, Marila De Luca, Giulia Petruz, Giuseppe Damante, Sandra Kraljević Pavelić

Open access · bronzeAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Alessandra Franzoni1 Medical Genetics Institute, Azienda Ospedaliero-Universitaria di Udine, Udine 33017, Italy.
Elitza Markova-Car2 Department of Biotechnology, Centre for High-Throughput Technologies, University of Rijeka, Rijeka 51000, Croatia.
Sanja Dević-Pavlić2 Department of Biotechnology, Centre for High-Throughput Technologies, University of Rijeka, Rijeka 51000, Croatia.
Davor Jurišić3 Department for Plastic and Reconstructive Surgery, Clinic for Surgery, University Hospital Centre Rijeka, Rijeka 51000, Croatia.
Cinzia Puppin4 Department of Medical and Biological Sciences, University of Udine, Udine 33100, Italy.
Catia Mio4 Department of Medical and Biological Sciences, University of Udine, Udine 33100, Italy.
Marila De Luca4 Department of Medical and Biological Sciences, University of Udine, Udine 33100, Italy.
Giulia Petruz4 Department of Medical and Biological Sciences, University of Udine, Udine 33100, Italy.
Giuseppe Damante1 Medical Genetics Institute, Azienda Ospedaliero-Universitaria di Udine, Udine 33017, Italy.
Sandra Kraljević Pavelić2 Department of Biotechnology, Centre for High-Throughput Technologies, University of Rijeka, Rijeka 51000, Croatia.
University of Udine · ITUniversity of Rijeka · HROspedale Santa Maria della Misericordia di Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circadian clock regulation in mammals is controlled by feedback loops of a set of circadian genes. One of these circadian genes, NPAS2, encodes for a member of the bHLH-PAS class of transcription factors and is expressed in the forebrain and in some peripheral organs such as liver and skin. Other biological processes are also regulated by circadian genes. For example, NPAS2 is involved in cell proliferation, DNA damage repair and malignant transformation. Aberrant expression of clock genes has been previously observed in melanoma which led to our effort to sequence the NPAS2 promoter region in this cancer type. The NPAS2 putative promoter and 5' untranslated region of ninety-three melanoma patients and ninety-six control subjects were sequenced and several variants were identified. Among these is a novel microsatellite comprising a GGC repeat with different alleles ranging from 7 to 13 repeats located in the 5' untranslated exon. Homozygosity of an allele with nine repeats (9/9) was more prevalent in melanoma than in control subjects (22.6% and 13.5%, respectively, P: 0.0206) suggesting that some NPAS2 variants might contribute to melanoma susceptibility. Impact statement This report describes a variable microsatellite repeat sequence located in the 5' untranslated exon of NSPAS2, a gene encoding a clock transcription factor. Significantly, this study is the first to show that a variant copy number GGC repeat sequence in the NPAS2 clock gene associates with melanoma risk and which may be useful in the assessment of melanoma predisposition.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Genetic5' Untranslated RegionsAllelesBasic Helix-Loop-Helix ProteinsFemaleHumansMaleMelanomaMicrosatellite RepeatsNerve Tissue ProteinsPromoter Regions, GeneticRepetitive Sequences, Nucleic Acid5' Untranslated RegionsBasic Helix-Loop-Helix ProteinsNerve Tissue ProteinsNPAS2 protein, humanclock genesmelanomamicrosatellite repeatsNPAS2

Identifiers

PMID28799406
PMCPMC5648290
OpenAlexW2744797634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.